Eli Lilly Crushes Q2 Estimates as Mounjaro and Zepbound Sales Surge, Raising 2026 Revenue Outlook

 Eli Lilly Crushes Q2 Estimates as Mounjaro and Zepbound Sales Surge, Raising 2026 Revenue Outlook

**The pharmaceutical giant delivered a 48% revenue jump to $22.97 billion, powered by blockbuster GLP-1 sales and international expansion, prompting a full-year guidance hike that sent shares soaring .**

---

## The Numbers That Matter: A Blowout Quarter

Eli Lilly's second-quarter results were nothing short of spectacular, demonstrating the immense and still-growing demand for its metabolic medicines. The company's performance was driven by a dual-pronged success: the explosive growth of its flagship drugs in the U.S. and a massive international expansion, particularly in China.

**The key headline figures:**

- **Revenue:** $22.97 billion, up 48% year-over-year, well above the consensus estimate of about $20.73 billion .

- **Non-GAAP EPS:** $8.38, a 33% increase from a year ago, crushing the $6.01 estimate .

- **Net Income:** $7.1 billion, or $7.94 per share, up from $5.7 billion a year earlier .

- **Global Volume Growth:** 60% increase, showcasing the sheer scale of patient adoption .

### The Metabolic Engine: Mounjaro and Zepbound

The stars of the quarter were, once again, the company's GLP-1 therapies.

| Drug | Q2 2026 Revenue | Year-over-Year Change |

| :--- | :--- | :--- |

| **Mounjaro** | $9.94 billion | **+91%** |

| **Zepbound** | $4.93 billion | **+44%** |

*Source: CNBC, Yahoo Finance *

Mounjaro's worldwide revenue surged, fueled by a massive **172% jump in international sales** following its inclusion on China's National Reimbursement Drug List . This single move offset a 36% drop in realized prices outside the U.S. . In the U.S., where Mounjaro and Zepbound prescription volumes continue to rise, revenue climbed 33% on the back of strong demand .

### Foundayo's Debut: The Oral Pill Arrives

The second quarter marked the first earnings report including sales of Lilly’s newly launched obesity pill, **Foundayo**, which won U.S. approval in April . The new GLP-1 pill brought in **$98 million** in its first reported quarter, in line with analyst expectations of about $103 million . This launch puts Foundayo in direct competition with a rival oral drug from Novo Nordisk, setting the stage for the next battle in the GLP-1 market .

### Managing Lower Prices for Massive Volume

Lilly is demonstrating a clear strategy: prioritize volume over price to capture market share and establish a dominant global position. The **60% volume growth** was partially offset by a **13% decline in realized prices** .

- **U.S. Strategy:** Volume increased by 37%, while realized prices dropped by 3% .

- **International Strategy:** The massive 113% volume surge came with a 36% price decline, largely linked to Mounjaro's addition to China's formulary .

CEO Dave Ricks described the trade-off as a calculated move to "expand the market" and make these therapies accessible to a wider patient base .

## A Historic M&A Spree

Fueled by its massive financial windfall, Lilly is engaging in a historic acquisition spree. The company recently struck a deal to buy a psychedelics drugmaker in July and also announced plans to buy three vaccine makers in May . The aggressive business development is a strategic deployment of record cash flows to secure a pipeline for the future.

The company's second-quarter results included **$3.03 per share in charges** tied to these acquisitions . This is why, despite raising the underlying EPS guidance by $2.78, the full-year adjusted EPS outlook remained relatively flat at **$35.50 to $36.50** .

## The New Growth Engine: Manufacturing Expansion

Lilly is investing heavily in its manufacturing capacity to keep pace with demand. The company committed an additional **$4.5 billion** to expand its Indiana manufacturing sites . By investing in manufacturing while its competitors struggle to catch up, Lilly is creating a new competitive advantage.

## Looking Ahead: A "Brighter Future"

Eli Lilly's outlook for the rest of 2026 is more robust than ever. The company raised its full-year revenue guidance to **$85 billion to $87 billion**, up from the previous $82 billion to $85 billion and ahead of the Wall Street consensus . The performance margin guidance also improved, with Lilly now expecting margins between 49.0% and 50.5% .

CEO David Ricks highlighted that the market for GLP-1 therapies is only expanding, projecting global use will rise from approximately 20 million patients at the end of 2025 to 30 million by the end of 2026 .

Lilly shares rose nearly 7% in early trading following the report, reflecting investor confidence in the company's strategy of volume-driven growth and sustained pipeline innovation . The next chapter for investors will be watching whether the company can maintain this momentum through the second half and into 2027.

---

## Frequently Asked Questions

### Q: How much revenue did Eli Lilly report for Q2 2026?

A: Eli Lilly reported revenue of **$22.97 billion** for the second quarter of 2026, representing a 48% increase from the same period a year earlier . This beat the Wall Street consensus estimate of roughly $20.6 billion .

### Q: What is Eli Lilly's new revenue guidance for 2026?

A: Following the strong Q2 results, Eli Lilly raised its full-year 2026 revenue outlook to between **$85 billion and $87 billion**, up from its previous range of $82 billion to $85 billion .

### Q: How did Mounjaro and Zepbound perform in the quarter?

A: Both drugs delivered exceptional growth. Mounjaro's worldwide revenue jumped **91% to $9.94 billion** . Zepbound's U.S. revenue rose **44% to $4.93 billion**, surpassing analyst expectations .

### Q: What is Foundayo and how much revenue did it generate?

A: Foundayo is Eli Lilly's newly launched oral obesity pill that won U.S. approval in April 2026 . It generated **$98 million** in sales for the second quarter, its first full quarter on the market .

### Q: Why did Eli Lilly's EPS guidance not increase as much as revenue?

A: Eli Lilly's underlying EPS guidance was raised by $2.78 per share at the midpoint, but this was more than offset by **$3.03 per share in charges** tied to acquisitions, resulting in a full-year EPS range of $35.50 to $36.50 .

### Q: What is Eli Lilly's strategy for dealing with lower drug prices?

A: Eli Lilly is prioritizing volume growth. The strategy accepts lower realized prices in exchange for capturing a larger market share, resulting in a 60% volume increase that is more than compensating for the 13% price decline globally .

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and company performance are subject to rapid change. Past performance is not indicative of future results. You should consult with a qualified financial advisor before making any investment decisions.